Jianfeng Group Lin2016 -031 (Announcement on Signing Letter of Intent for Foreign Investment of Subsidiates)
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 公告编号:2016-031
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于子公司对外投资签署合作意向书的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l 交易简要内容:本公司控股子公司浙江尖峰药业有限公司近日与桂林商源植物制品有限公司签订了《合作意向书》,拟以北京慧宝源生物技术有限公司及其子公司为平台与其开展医药业务的合作。
l 本次交易不构成关联交易
l 本次交易不构成重大资产重组
l 本次签订的是合作意向书,是合作谈判的基础,该合作事项是否能够实现存在不确定性。
一、对外投资概述
(一)本公司控股子公司浙江尖峰药业有限公司(以下简称:尖峰药业)近日与桂林商源植物制品有限公司(以下简称:桂林商源)签订了《合作意向书》,拟以现金出资,以增资扩股、受让股权的方式成为桂林商源子公司北京慧宝源生物技术有限公司(以下简称:北慧生物)的股东,以北慧生物及其子公司广西慧宝源医药科技有限公司(以下简称:广慧科技)为平台开展医药业务的合作。
(二)本次签订的是合作意向书,是合作谈判的基础。具体事宜尚需根据审计、评估、尽职调查结果进一步协商谈判。正式合作协议,还将依照《股票上市规则》、公司《章程》等的规定,经决策程序审议。
(三)该合作事项不属于关联交易,也不构成《上市公司重大资产重组管理办法》规定的重大资产重组情况。
二、合作方的基本情况
1、企业名称:桂林商源植物制品有限公司
2、企业性质:有限责任公司(外商合资)
3、注册地:桂林灵川八里街开发区
4、注册日期:2003年10月23日
5、主要办公地点:广西省桂林市八里街开发区灵川大道33号
6、法定代表人:詹姆斯 周
7、注册资本:捌万美元整
8、经营范围:生产、销售植物脱水制品(涉及前置许可的项目除外)。(依法须经批准的项目,经相关部门批准后方可开展经营活动。)
9、主要股东:
|
序号 |
股东名称或姓名 |
出资额(万美元) |
出资比例 |
|
1 |
詹姆斯 周 |
4.4 |
55% |
|
2 |
周文迪 |
3.6 |
45% |
注:詹姆斯 周和周文迪是夫妻关系。
10、经北京汉根会计师事务所有限公司审计,截至2015年底,桂林商源的资产总额4539.72万元、资产净额4540.68万元,2015年度的营业收入0万元、净利润33.42万元。截至2016年半年度末,桂林商源的资产总额10273.06万元、资产净额4530.29万元,2016年半年度的营业收入0万元、净利润-2.85万元;2016年半年度财务数据未经审计。
三、合作标的基本情况
(一)标的公司的基本情况
1、企业名称:北京慧宝源生物技术有限公司
2、企业性质:有限责任公司(外商投资企业与内资合资)
3、注册地:北京市海淀区开拓路5号A区四层A407、A408室
4、注册日期:2011年07月15日
5、主要办公地点:北京市昌平区生命园路20号院7号楼402室
6、法定代表人:周詹姆斯(与桂林商源的法定代表人詹姆斯 周为同一人)
7、注册资本:8000万元
8、经营范围:技术推广、技术转让、技术咨询、技术服务;医学研究与试验发展;技术进出口。
主要通过其子公司广慧科技开展医药产品的生产和销售业务。广慧科技成立于2013年3月,注册资本20000万元(其中北慧生物占75%),住所:中马钦州产业园区中马大街1号,其新建的生产基地设在中国-马来西亚钦州产业园,占地214.46亩,多个剂型的生产车间已基本建成,待通过GMP认证后可投入生产。广慧科技主要从事医药技术开发研究;医药建设项目投资、咨询;颗粒剂、中药前处理和提取、合剂(口服液)、糖浆剂、酊剂(内服、外用)、搽剂、酒剂、片剂生产、销售;新药技术的引进等。2016年广慧科技通过受让药品相关技术的方式,目前已经拥有以中成药制剂为主的76个药品批文,主要产品有:藿香正气水、十滴水、陈香露白露片、复方珍珠解毒口服液、益肝明目口服液等。公司拥有较强的对外合作及新药研发能力,获得了美国耶鲁大学和佐治亚大学研究基金会股份有限公司的“曲沙他滨”抗癌结构专利、治疗方法和全球商业化开发授权;“克来夫定”抗乙肝病毒的中国商业化开发授权;“克来夫定”抗癌结构专利、治疗方法及抗癌全球商业开发优先权。2016年8月,注射用“曲沙他滨”抗肝癌获得了国家食品药品监督管理局颁发的《药物临床试验批件》(批件号:2016L07060),目前正在进行一期临床试验方案的编制工作。
9、主要股东:
|
序号 |
股东名称 |
出资额(万元) |
出资比例(%) |
|
1 |
桂林商源 |
57,437,300 |
71.80 |
|
2 |
何龙飞 |
10,160,000 |
12.70 |
|
3 |
北京慧宝源企业管理有限公司 |
10,000,000 |
12.50 |
|
4 |
其他14名自然人股东 |
2,402,700 |
3.00 |
注:北京慧宝源企业管理有限公司成立于2010年11月18日,法定代表人是周詹姆斯,注册资本为5000万元(其中:桂林商源占有51%),经营范围:企业管理。
(二)截至2015年年底,北慧生物的资产总额28501.85万元、资产净额4034.73万元,2015年度的营业收入80万元、归属于母公司所有者净利润-537.39万元;截至2016年半年度末,北慧生物的资产总额33963.65万元、资产净额14758.21万元,归属于母公司所有者权益合计10250.11万元。2016年半年度的营业收入631.19万元、归属于母公司所有者净利润63.90万元。以上财务数据经具有证券、期货从业资格的中审华寅五洲会计师事务所审计。
(三)北慧生物最近12个月内的增资情况。
最近12个月内,北慧生物进行了3次增资,分别为:
1、2016年3月,北慧生物的注册资本由1000.00万元增至2016.00万元,由何龙飞以人民币增资5,000.00万元,其中1,016.00万元计入实收资本,3,984.00万元计入资本公积。
2、2016年6月,北慧生物的注册资本由2,016.00万元增至7,759.73万元,由桂林商源植物制品有限公司以货币增资5,743.73万元。
3、2016年6月,北慧生物的注册资本变更为8,000.00万元,由14名自然人股东出资人民币600.675万元。其中240.27万元计入实收资本,360.405万元计入资本公积。
四、合作意向书的主要内容
2016年10月8日,桂林商源(甲方)和尖峰药业(乙方)签订了《合作意向书》,主要条款有:
(一)合作方式
甲拟引入乙方为北慧生物的股东,乙方拟以现金出资以增资扩股、受让股权的方式成为北慧生物的股东,具体比例和方式另行协商。
(二)后续工作安排
1、双方共同成立工作组,对合作事宜进行认证,并开展其他相关工作。
2、聘请审计、评估、法律等相关中介机构,做好财务审计、资产评估、法律尽调等前期准备工作。甲方应积极配合乙方及中介机构的尽职调查工作。
(三)排他事项
除非经乙方书面同意,在本意向书签订后3个月内(简称:排他期),甲方及其控制的任何代表人不能直接或间接寻求与任何第三方就北慧生物、广慧科技的股权事宜进行接洽、磋商、谈判或签署任何协议或意向书(不论该协议或意向书是否对其有约束力),但是,甲方与北慧生物、广慧科技原股东就本意向书所述事项商谈不受前述限制。
(四)其他事项
1、本意向书为双方就合作事宜所达成的初步意向,并作为双方开展工作的基础。为推进合作进程,双方将保持沟通,及时磋商与落实相关事宜。
2、双方将在尽职调查和取得北慧生物、广慧科技原股东认可的基础上,尽快开展具体合作事宜的谈判,并签订相关协议。
3、就双方为本次合作而做工作获取的资料以及本意向书所述事宜,除相关法律、法规或证券监管规定外,如果事先没有得到对方的书面同意,任何一方在任何时候不得为任何其他目的使用或许可他人使用或向第三方披露该等信息。
五、本次合作对公司的影响及风险提示
本次合作是根据公司“合作创新强主业、规范科学求发展”战略方针,是做大做强医药业务的具体实施,如果该项合作能顺利完成,将进一步扩大公司医药主业的规模。
鉴于本次签署的是合作意向书,具体合作事宜尚需在审计、评估、尽职调查的基础上进一步协商谈判,并签订相关协议,还将根据《股票上市规则》、公司《章程》等的规定履行董事会或股东大会的审议程序,该合作是否能够实现存在不确定性;同时,新药研发的周期长、投入大、风险高,北慧生物、广慧科技的新药研发、临床试验结果具有一定的不确定性。
公司将根据合作事项的进度及时披露后续进展情况,敬请广大投资者注意投资风险。
特此公告
浙江尖峰集团股份有限公司
董事会
二〇一六年十月十一日
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05